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Abstract After months of restrictive containment ef-
forts to fight the severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) epidemic, European
countries are planning to reopen. To support the process,
we conducted a cross-sectional survey among the Hun-
garian population to estimate the prevalence of
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infectious cases and prior SARS-CoV-2 exposure. A
representative sample (n = 17,787) for the Hungarian
population of 14 years or older living in private house-
holds (n = 8,283,810) was selected. The study was per-
formed within 16 days after 50 days of restrictions,
when the number of confirmed cases was stable low.
Naso- and oropharyngeal smears and blood samples
were collected for PCR and antibody testing. The testing
was accompanied by a questionnaire about symptoms,
comorbidities, and contacts. Design-based prevalence
estimates were calculated. In total, 10,474 individuals
(67.7% taken into account a sample frame error of 2315)
of the selected sample participated in the survey. Of the
tested individuals, 3 had positive PCR and 69 had
positive serological test. Population estimate of the
number of SARS-CoV-2 infection and seropositivity
were 2421 and 56,439, respectively, thus active infec-
tion rate (2.9/10,000) and the prevalence of prior SARS-
CoV-2 exposure (68/10,000) was low. Self-reported
loss of smell or taste and body aches were significantly
more frequent among those with SARS-CoV-2. In this
representative, cross-sectional survey of the Hungarian
population with a high participation rate, the overall
active infection rate was low in sync with the prevalence
of prior SARS-CoV-2 exposure. We demonstrated a
potential success of containment efforts, supporting an
exit strategy. NCT04370067, 30.04.2020.
Keywords SARS-CoV-2 . Cross-sectional . COVID-
19 . Nationwide . Hungary
Introduction
With the outbreak of the corona virus disease 2019
(COVID-19) pandemic, efforts to estimate the total
number infections and to investigate the prior exposure
to severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) are key elements of developing defen-
sive responses. (WHO announces COVID-19 outbreak
a pandemic 2020; Guan et al. 2020) International health
organizations endorsed general recommendations of
strategic preparedness and outlined preventive measures
as a part of a response plan in support of all countries.
(Coronavirus Disease 2019 (COVID-19) 2020a; Coun-
try and Technical Guidance—Coronavirus disease
(COVID-19) 2020) Even though these recommenda-
tions were incorporated almost universally, each coun-
try has experienced a distinct course of the epidemic
depending on the timing of safety measure initiation and
the degree of compliance with the restrictive measures.
In Europe, the first cluster of cases were confirmed
on February 21 in Lombardy, Italy (Onder et al. 2020)
(~ 450 miles away from Hungary). As of March 13,
Europe was declared to be the active center of the
COVID-19 pandemic by the World Health Organiza-
tion. (Coronavirus disease 2019 (COVID-19) 2020b)
In Hungary, the first two SARS-CoV-2 cases were
diagnosed on March 4 (university students who had
returned from Asia). By March 11, altogether 16
laboratory-confirmed infections as well as 1 COVID-19–
related death were registered. At that time, a state emer-
gency was declared and universities were closed. Subse-
quently from March 16, further restrictions were intro-
duced, such as prohibition of public gatherings of more
than 100 people, closing elementary and high schools,
reducing the opening hours of restaurants and cafes, as
well as permitting the entry to Hungary of citizens only.
Subsequently, on March 28, general lockdown was
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announced, public events were canceled, and only grocery
stores and pharmacies were allowed to remain open; at the
time 343 confirmed cases were registered and 11 SARS-
CoV-2–related death occurred. Some of the safety mea-
sures concentrated only on the most vulnerable segment of
the population, the elderly. One example is selective open-
ing hours, providing a period of the day, when the grocery
stores, pharmacies, and markets were only open for indi-
viduals aged 65 or older.
After around 6 weeks of lockdown, a slow opening
of the economy was initiated within countries across
Europe. However, in order to safely and effectively
execute such a complex process, estimating the total
number of infective cases and the prevalence of previ-
ous exposure to the pathogen is essential. Investigation
of the SARS-CoV-2 virulence and case severity has
been extensively studied among patients with severe
disease course. (Guan et al. 2020; Onder et al. 2020)
However, in order to reveal the full spectrum of disease
and adjust public health safety measures accordingly,
the rate of mild or asymptomatic infections that do not
require medical attention need to be explored. (Lipsitch
et al. 2020)
The objective of the present study was to estimate the
total number of infectious cases and the prevalence of
prior SARS-CoV-2 exposure in the Hungarian popula-
tion after 50 days of strict containment measures. The
study was conducted to support the development of an
exit policy from the currently applied safety restrictions.
Methods
Study design, patient population
The study was funded by the 2020-2.1.1-ED-2020-
00017 grant and was approved by the institutional re-
view board and the local ethics committee (IRB IV/
4060-3/2020/EKU).
The target population included individuals aged
14 years or older, living in private households in Hun-
gary. A two-stage stratified probability sample of indi-
viduals was selected from the population registry,
selecting settlements as primary sampling units (PSU)
at the first stage and individuals at the second stage. To
obtain equal precision in each region, seven regional
samples of equal size were designed. Within each re-
gion, the larger settlements as well as settlements with at
least five confirmed cases became certainty PSUs. The
181 certainty PSUs cover 55% of the target population
and 82% of the overall number of confirmed cases.
Within each region, settlements with one to four con-
firmed cases constituted separate strata and the rest of
PSUs were stratified by size, taxable income per capita,
and population with tertiary educational level. Overall,
154 strata were defined this way and two PSUs were
selected with probability proportional to size within
each strata. Altogether, 489 settlements from 3155 were
selected.Within the settlements, individuals were select-
ed by systematic random sampling after ordering them
by age, as age had been identified as the single most
important factor associated with the severity of the
infection. A minimum of four individuals were selected
from each selected settlement. The total number of the
sample size was determined by assuming 10% sampling
frame error and 70% participation rate. Thus, 17,787
individuals were selected to ensure a planned effective
sample size of 11,206. To ensure the temporally cross-
sectional nature of the study, the data collection period
was restricted to 16 days that fell under the same restric-
tion regulations starting on May 1.
Those participants were included in the final study
population who had either PCR test or serological test-
ing with a completed questionnaire (Fig. 1).
Contacting selected individuals
We informed selected individuals with an official invi-
tation letter via mail. Those who had previously autho-
rized to be contacted officially by e-mail received an
additional invitation electronically. In addition, 14,250
participants with a telephone number registered in the
administrative databases were contacted by phone by
the Central Statistical Office and the universities. Al-
most 3000 general practitioners and the local munici-
palities provided help to contact and motivate the se-
lected participants. Finally, those who we failed to be
contacted were visited on their registered address.
Screening process and sample collection
Screening was carried out as a collaborative effort of
four medical universities across Hungary (Semmelweis
University, University of Debrecen, University of Sze-
ged, University of Pécs) and the Hungarian Central
Statistical Office. Individuals selected for screening
were required to register online or over the phone
through a dedicated line. The samples were collected
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by 187 screening teams in 348 fixed screening posts, in
five screening buses, and by mobile testing units
through a personal visit to those who could not be
mobilized. These efforts were supported by the ambu-
lance service, municipalities, and local governmental
offices.
Laboratory measurements
PCR test
To detect or exclude the presence of SARS-CoV-2
virus, nasopharyngeal and oropharyngeal samples were
collected in viral transport medium tubes and were
transported to the laboratory at 2–8 °C. After nucleic
acid extraction, real-time PCR was performed (HBRT-
COVID-19; Chaozhou Hybribio Biochemistry Ltd.,
Chaozhou, Guangdong, China) (Organization WH
2020). PCR was performed within 24 h after sample
collection. The test used detects the presence of two
SARS-CoV-2 viral genes and also applies a human gene
sequence as an internal quality control for sampling. The
absence of amplified human gene in PCR product indi-
cates inappropriate sampling. Patients with inappropri-
ate samples were re-sampled the day after and provided
samples that were appropriate for testing. Those who
tested positive were informed within 2 days and were
required to self-isolate for 2 weeks. Positive test results
were also reported toward the Hungarian Health Au-
thorities. Participants had access to their own results via
the National eHealth Infrastructure.
Blood sample analysis
For serological testing, blood samples were obtained
from all participants at the age of 18 or older; under
18 years of age, blood testing was optional. Serological
testing for SARS-CoV-2–specific IgG was analyzed
with commercially available Food and Drug
Administration–approved immunoassay (SARS-CoV-
2 IgG Reagent Kit Cat. No. 6R86-32 on Architect
i2000SR instruments; Abbott Laboratories, Irving, TX,
USA), (Abbott 2020) and the remnant samples were
stored at − 80 °C.
Questionnaire
All participants were invited to fill out a question-
naire during the registration process online, over
the phone, or during the screening in person. The
questionnaire contained questions regarding socio-
economic status, risk factors (smoking and body
mass index—BMI), comorbidities, adherence to
safety measures, recent travel history, history of
symptoms suggestive for COVID-19, and history
of a known contact with a confirmed SARS-CoV-
2– infected individual or with a person in
quarantine.
Definition of confirmed cases
To provide a comprehensive background of the
COVID-19 epidemic in Hungary, beyond the re-
sults of this current survey, we report the age, sex,
and regional distribution of all reported confirmed
cases and COVID-19–related mortality registered
in Hungary until May 16 according to the National
Public Health Center. We provide this data for
individuals at the age of 14 years or older, living
in private households and separately for those liv-
ing in institutions (homeless shelter, long-term care
facility or nursery home).
Statistical analysis
We estimated the population prevalence of acute infec-
tion and seropositivity by age, sex, and region, catego-
ries of labor activity, contact with a person infected with
SARS-CoV-2 or being in quarantine, and by visiting a
foreign country since March 1, 2020. To reduce
bias in weighting, we could use several area-,
dwelling unit-, and individual-level auxiliary infor-
mation from sampling frame and other administra-
tive data sources, each related to both non-
response and the objective variable. After adjusting
design weights, the response sample was calibrated
to known population counts by region, sex, and
age categories. Variance estimation method took
calibration effect as well as stratification and clus-
tering into account. For the residuals by calibration
variables, we used Taylor-linearized variance esti-
mation. (Wolter 2007) In case of zero observation
in a subgroup, we used the rule-of-three method to
estimate confidence intervals (i.e., 95% confidence
interval of the prevalence was estimated as 0–3/n).
(Eypasch et al. 1995) The calculations were per-
formed using SAS software version 9.4.
GeroScience
Results
Of the planned calculated sample of 17,787 individuals,
10,505 underwent PCR testing and 10,504 had a sero-
logical test, while 10,434 had both. In total, 12,236
individuals completed the questionnaire. Altogether,
10,474 people, 67.7% of the 15,472 individuals belong-
ing to the sampling frame, who had either a PCR or a
serological test with a completed questionnaire, were
included into our final study population (Fig. 1). The
mean age was 48.7 years and the 46.4% were male
(Table 1). The population estimate of the proportion of
individuals who experienced any symptoms suggestive
for SARS-CoV-2 infection was larger among those with
a positive PCR or immunological test compared with
seronegative persons: 54.7% vs. 42.2% (Fig. 2c). Body
aches and loss of smell or taste occurred significantly
more frequently among people with a positive test
(19.0%, 95% CI 8.6–29.3% vs. 7.8%, 95% CI 7.2–
8.4%, and 14.1%, 95% CI 5.8–22.4 vs. 2.6%, 95% CI
2.3–2.9%, respectively). Shortness of breath and diar-
rhea was also a common symptom in the seropositive
group, although compared with the seronegatives, the
difference was not statistically significant. The estimat-
ed proportion in the population of people who had any
comorbidities was higher among persons with a positive
test: 54.4% vs. 41.5% (Fig. 2d).
Test results in the studied population
Three participants had a positive PCR test; two of them
were hospitalized due to confirmed COVID-19 infec-
tion. Altogether, 70 individuals had a positive serolog-
ical test result, 69 with a completed questionnaire. Of
the seropositive individuals, two had a simultaneous
positive PCR test.
Estimated population infection rate
Based on the results of the survey, the estimated number
of PCR-positive and seropositive individuals in the en-
tire Hungarian population 14 years or older who live in
independent households (n = 8,283,810) were 2421 and
56,439, respectively.
Fig. 1 Formulation of the study
population. *The sum of the
number of positive and negative
tests do not add up to the number
of the study population (10,474)
neither for PCR nor for serology
as some persons consented to
provide only one type of samples
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The estimates in Table 2 suggest that seropositiv-
ity tends to increase by age (between 14 and
39 years—56/10,000 vs. 65 years or older—83/
10,000) and is higher among those who commuted
Table 1 Characteristics of the study population
Total study population
(n = 10,474)
Test positive*
(n = 70)
Seronegative without
positive PCR
(n = 10,336)
Negative PCR test
without serology
(n = 68)
Men (%) 4864 (46.4) 35 (50.0) 4798 (46.4) 31 (45.6)
Age (years)
Mean (SD) 48.7 (18.0) 52.2 (18.2) 48.7 (18.0) 45.1 (21.3)
14–39 (%) 3353 (32.0) 18 (25.7) 3309 (32.0) 26 (38.2)
40–64 (%) 4735 (45.2) 33 (47.1) 4676 (45.2) 26 (38.2)
65– (%) 2386 (22.8) 19 (27.1) 2351 (22.7) 16 (23.5)
BMI (kg/m2)†
<18.5 322 0 315 7
18.5–24.9 3709 21 3662 26
25–29.9 3589 27 3546 16
30– 2774 20 2736 18
Smoking†
Never 5381 38 5310 33
Current 2933 16 2904 13
Past 2143 15 2107 21
Any symptoms after 03.01.2020‡ 4470 37 4406 27
Fever 239 3 233 3
Fatigue 883 9 868 6
Body aches 832 12 817 3
Cough 1630 13 1609 8
Headache 2548 19 2513 16
Sore throat 1290 8 1276 6
Shortness of breath 432 6 425 1
Abdominal pain 471 4 467 0
Nausea/vomiting 333 1 332 0
Diarrhea 773 10 758 5
Loss of smell or taste 277 12 261 4
Reported any comorbidities‡ 4533 38 4461 34
Hypertension 3549 32 3489 28
Heart disease 1135 11 1115 9
Diabetes mellitus 1059 7 1045 7
Chronic pulmonary disease 522 8 505 9
Chronic renal disease 262 3 256 3
Chronic liver disease 141 3 137 1
Current malignancy 262 2 256 4
Immunodeficiency 201 1 200 0
The relative frequencies of men and age categories in the population are the same as in the sample, as the weights were calibrated to these
characteristics. The population estimates of the other relative frequencies are presented in Fig. 2
*Either with positive PCR or positive serological test
†As some of the participants did not answer the question, the percentages do not add up to 100%
‡More than one category could be indicated
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regularly to their workplace (commutes several
times—59/10,000 vs. worked from home—42/
10,000), had a contact with confirmed SARS-CoV-
2–infected individual or someone in quarantine (in-
dividuals with a history of contact—114/10,000 vs.
without a contact—66/10,000), and traveled abroad
after March 12, 2020 (traveled abroad—106/10,000
vs. no travel—67/10,000). However, none of these
differences were statistically significant.
By large statistical region, the highest prevalence of
seropositivity was found in the central region including
the capital, Budapest (Fig. 3). By subregion, the differ-
ence was larger between Budapest (90/10,000) and the
two least developed regions: Southern Transdanubia
(46/10,000) and Northern Hungary (45/10,000)
(Table 3).
The total number of the reported confirmed cases by
the National Public Health Center in Hungary until the
end of the study was 3464, of whom 2580 lived in private
households andwere 14 years or older. In the latter group,
the number of confirmed new cases during the study
period of May 1–16 ranged between 15 and 56, an
average 27 per day. The number of registered deaths
was 350 and 101 among persons living in private house-
holds and in institutions, respectively. The age distribu-
tion of the confirmed cases reported until May 16 living
in private households was similar to the age distribution
of the test-positive subjects identified in the survey
(Table 4). The regional variation was larger in the con-
firmed cases than in seropositive ones: among those who
live in private households, 61% of the confirmed cases
occurred in the Central region, whereas seropositive in-
dividuals were distributed evenly by large statistical re-
gion (Tables 3 and 4). The sex and regional distributions
of the confirmed cases were identical among those who
lived in private households and in institutions. On the
Fig. 2 Population estimates of the distribution of smoking (a), body mass index (b), symptoms (c), and comorbidities (d) by infection
GeroScience
other hand, the proportion of elderly people was twice as
large in the latter group than in the former.
Discussion
In the H-UNCOVER representative, cross-sectional popu-
lation survey of Hungarian individuals, we investigated the
total number of active infections and prevalence of virus
exposure after 50 days of the initiation of containment
regulations. We provide the first comprehensive analysis
utilizing PCR and serological testing simultaneously. Of
the selected representative population sample, 67.7% was
tested and completed the questionnaire resulting in a con-
siderably high participation rate. Despite the close proxim-
ity of major infectious clusters, due to the early
introduction of containment efforts, the overall active in-
fection rate remained low (2.9/10,000), in sync with the
prevalence of SARS-CoV-2 exposure (68/10,000).
The relatively higher rate of participation in comparison
with similar studies conducted to describe the epidemic of
SARS-CoV-2 (Gudbjartsson et al. 2020) could be attrib-
uted to multiple factors. First, in order to mobilize as many
participants as possible, we contacted individuals on three
parallel levels: each person was notified via mail and over
the phone; as well as general practitioners from around the
country contacted selected individuals from their practice.
Second, investigators of our study were supported by local
governors and themedia to spread information to reach out
to as many individuals as possible. Third, to enhance the
accessibility of testing units, we established even distribu-
tion of designated testing facilities and mobile testing units
Table 2 Population estimates of PCR-positive and seropositive cases
PCR positive Seropositive
Estimated total number Prevalence per 10,000
(95% CI)
Estimated total number Prevalence per 10,000
(95% CI)
Total 2421 2.9 (0–6.7) 56,439 68 (50–86)
Men 713 1.8 (0–5.8) 27,323 70 (44–95)
Women 1708 3.9 (0–10) 29,115 67 (42–92)
Age (years)
14–39 0 0 (0–8.9) 16,637 56 (27–86)
40–64 1269 3.7 (0–11) 24,127 70 (44–96)
65– 1152 6.1 (0–16) 15,674 83 (39–126)
Labor activity
Active worker 1269 3.0 (0–9.0) 22,406 53 (33–74)
Pensioner 1152 5.4 (0–14) 23,412 109 (66–152)
Student, not working 0 0 (0–38) 4932 69 (0–149)
Housewife 0 0 (0–142) 1239 73 (0–174)
Other non-worker 0 0 (0–27) 4450 43 (1.6–84)
Place of work during the epidemic*
Commutes several times a week 1269 4.3 (0–13) 17,329 59 (33–84)
Commutes once a week 0 0 (0–93) 948 40 (0–130)
Home based 0 0 (0–25) 4128 42 (7.7–76)
Known contact with a confirmed SARS-CoV-2–infected person or a person being in quarantine
Yes 0 0 (0–73) 3386 114 (24–204)
No 2421 3.1 (0–7.0) 52,044 66 (48–84)
Refused to answer 0 0 (0–252) 1009 106 (0–286)
International travel after 03.01.2020
Yes 0 0 (0–79) 3460 106 (12–200)
No 2421 3.1 (0–7.0) 52,979 67 (49–86)
*Only among active workers
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across the country. In addition, we provided in-person
visits for two reasons: to further improve the study partic-
ipation and to test individuals who were otherwise not
mobilizable. Lastly, the availability of participants in their
homes was considerably higher due to the quarantine and
travel restrictions.
In this survey, a relatively low active SARS-CoV-2
infection rate (0.029%) and in sync low overall seroposi-
tive rate was identified (0.68%). In Hungary, 12 days after
the first SARS-CoV-2–infected cases were confirmed,
restrictive measures were implemented. The authors be-
lieve that the early initiation of strict containment efforts
may explain the control of the spread of SARS-CoV-2
infection. It is important to underline that there were also
specific safety measures in Hungary solely applied to
elderly people, such as specific opening hours when only
the elderly population could visit markets, grocery stores,
or pharmacies. In addition, the adherence of the Hungarian
population to these regulations also has to be emphasized.
Data from different sources including online surveys,
Fig. 3 Estimated number and PCR positivity and seropositivity by statistical region
Table 3 Regional distribution of the target and the study population, and estimated PCR-positive and seropositive cases by region
PCR positive Seropositive
Region Total population Sample
size
Estimated total
number
Prevalence per
10,000 (95% CI)
Estimated total
number
Prevalence per
10,000 (95% CI)
Central
Budapest 1,480,190 987 1269 8.6 (0–26) 13,393 90 (29–152)
Pest county 1,087,523 768 0 0 (0–39) 6920 64 (9.4–118)
Transdanubia
Central Transdanubia 907,796 1606 439 4.8 (0–15) 6147 68 (29–107)
Western Transdanubia 853,686 1480 0 0 (0–20) 7215 85 (40–129)
Southern Transdanubia 747,675 1335 0 0 (0–22) 3465 46 (14–79)
Great Plain and Northern Hungary
Northern Hungary 942,357 1458 713 7.6 (0–24) 4236 45 (4.6–85)
Northern Great Plain 1,212,205 1406 0 0 (0–21) 8489 70 (22–118)
Southern Great Plain 1,052,378 1434 0 0 (0–21) 6574 62 (22–103)
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depersonalized aggregated mobile cell and traffic data
showed a drastic, 60–90% reduction in the number of
contacts and extreme reduction in mobility. (Röst et al.
2020) It has been shown with the use of mobility and
COVID-19 epidemiology data from the European coun-
tries that successful restrictive policy can significantly
contribute to the suppression of the SARS-CoV-2 pan-
demic. (Vokó and Pitter 2020)
Furthermore, consistently with the low level of sero-
positivity reported in our study, the rate of incident cases
registered by the National Public Health Center in Hun-
gary throughout the timeframe of the testing was low as
well. However, besides the early containment efforts,
there have been a few additional potential protective
factors suggested against COVID-19, such as BCG
vaccination or blood type 0 which is representative in
the Hungarian population. (Curtis et al. 2020; Zhao et al.
2020) In Hungary, BCG vaccination is mandatory, and
type 0 is relatively frequent, thus the population may
have lower susceptibility to SARS-CoV-2; however,
more robust evidence needs to be provided to prove
the protective effect of these factors.
The proportion of reported confirmed cases was sub-
stantially higher in the Central region of Hungary than
the proportion of seropositivity as identified via the
cross-sectional survey, which can be explained by the
higher rate of testing performed in this area: among
those with a PCR test performed until May 16, 43%
was obtained in the Central region, which represents
30% of the total population.
Our results suggest a higher SARS-CoV-2 infection
rate in older individuals and with persons with chronic
diseases, which have been shown to be a risk factor for
more severe disease course. (Grasselli et al. 2020) We
must also note that a large proportion of reported cases
occurred in institutions (Table 4),mainly in nursing homes.
Among them 74% were 65 years or older, and mortality
was much higher among elderly people. (Kemenesi et al.
2020) The reason for thismight be that in older individuals,
the immune response is less effective. Moreover, there is
evidence that in older individuals suffering from SARS-
CoV-1 infection, the switch from innate to adaptive im-
munity is impaired resulting in an insufficient antibody
production, which seems to be the case in SARS-CoV-2
infection as well. (Nikolich-Zugich et al. 2020) This high-
lights the need for specific interventions and safety mea-
sures in elderly care facilities as part of the exit strategy,
such as prolonged restrictive measures including strict
visitor policy, rigorous cleaning and disinfection protocols,
mandatory use of personal protective equipment by the
staff, appropriate training of the personnel, viral testing of
the new residents, frequent surveillance of symptoms sug-
gestive for SARS-CoV-2, and adequate policies and orga-
nization to isolate individuals with suspected infection.
In line with prior evidence, our data also showed that
loss of smell or tastemight be associatedwith SARS-CoV-
2 infection. (Spinato et al. 2020) We also found that
diarrhea was more common among seropositive people,
which is in accordance with the previously reported Italian
and Chinese data. (Lin et al. 2020; Buscarini et al. 2020)
Based on the results reported in the present study
exploring the epidemiology of SARS-CoV-2 exposure,
the development of an exit strategy from the currently
applied containment regulations is feasible. General regu-
lations considered to be essential to control the spread of
SARS-CoV-2, which were introduced all over the world,
were adapted inHungary in a relatively early phase. Due to
differences in the implementation of safety recommenda-
tions, however, each country may have its own character-
istic course of the epidemic. Therefore, we believe that
each country needs to survey their population in order to
learn their unique characteristic of COVID-19 epidemic
and to develop their individual strategic plan to establish a
transition back to normal everyday living and to resuscitate
the economy. We acknowledge that a sensitive balance
between people’s health and economy exists; however, an
early opening of the economy might undermine positive
effects of restrictive efforts. Our study suggests that early
initiation of safety measures and adherence to regulations
Table 4 Characteristics of the confirmed 14 years old and older
COVID-19 cases reported until May 16, 2020 in Hungary
Living in private
households
Living in
institutions
Men 1080 (41.9) 360 (40.7)
Women 1500 (58.1) 524 (59.3)
Region
Central 1583 (61.4) 547 (61.9)
Transdanubia 742 (28.8) 254 (28.7)
Great Plain and
Northern Hungary
255 (9.9) 83 (9.4)
Age (years)
14–39 525 (20.4) 50 (5.7)
40–64 1090 (42.3) 178 (20.1)
65– 965 (37.4) 656 (74.2)
The numbers in brackets are column percentages
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can decrease the spread of SARS-CoV-2 and result in low
COVID-19–related morbidity and mortality, especially
protecting the elderly (aged 65 and older) who are the
most vulnerable against the SARS-CoV-2 infection.
Results of the present study mirror the situation after
a time period of 50 days of safety restrictions. In order to
track the effect of economic reopening and loosening of
restrictive safety measures, repeating this representative
population-based cross-sectional survey with a nested
longitudinal follow-up of a subgroup is planned. More-
over, as future waves of COVID-19 are predicted, until
herd immunity is not obtained or until large-scale vac-
cination cannot be maintained, the need for such cross-
sectional surveys are even more pronounced.
Our survey had certain limitations. First, selective non-
response could be considered as a potential limitation;
however, it is very unlikely that the participation in the
study was related to a previously undiagnosed SARS-
CoV-2 infection. Second, while PCR testing is regarded
as the current standard diagnostic method for SARS-
CoV-2 infection, the risk of false negativity can be sig-
nificant and could be decreased significantly with repeat-
ed sampling which was not feasible in such a study.
In conclusion, our study suggests that early initiation
of containment efforts and adherence to regulations may
decrease the spread of SARS-CoV-2 and could result in
low COVID-19–related morbidity and mortality. Con-
sequently, an exit strategy from the currently applied
containment regulations is feasible.
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